Coronary Stent Market By Product Type (Drug-Eluting Stent, Bare-Metal Stent, and Bioresorbable Vascular Stent), By Material Type (Metallic, Cobalt Chromium (CoCr), Platinum Chromium (Pt-Cr), Stainless Steel, Nickel Titanium, and Others), By End-User (Hospitals, Cardiac Center, and Others), and By Region, Trends, Analysis and Forecast till 2034

Coronary Stent Market was valued at USD 7.5 Billion in 2024 and is projected to grow at a CAGR of 4.5% to reach USD 11.2 Billion by 2034.

Coronary stents (CS) are metallic expandable tubes inserted into coronary arteries and blocked due to an underlying condition called atherosclerosis. We refer to this revascularization process as coronary angioplasty with stent placement or percutaneous coronary intervention, PCI. Over the projection period, the demand for coronary stents is anticipated to be driven by an aging population and increasing rates of non-communicable diseases, including complicated lesions, diabetes, obesity, cardiovascular diseases (CVDs), and others.

Another factor that is anticipated to drive the usage of coronary stents throughout the forecast period is the growing desire for minimally invasive operations, or MIS. Smaller incision wounds result in greater patient satisfaction, which is one of the benefits of these techniques. Additionally, these techniques speed up healing and reduce hospital stays.

Due to improved DES and bioresorbable scaffolds, stent technology is becoming increasingly common than traditional balloon angioplasty. Introducing bifurcated stents and using biodegradable materials in coronary stent technology has improved and efficient outcomes for patients with cardiovascular disease (CVD). Businesses take the initiative to develop new products, form alliances, and engage in strategic partnerships. The factors above are anticipated throughout the projected period to fuel market expansion. However, throughout the forecast period, the high cost of these products and procedures, together with the strict regulatory clearance procedures for coronary stents, are anticipated to impede the expansion of the studied market.

Coronary Stent Market Key Drivers:

Continuous growth in the prevalence and incidences of heart diseases  

• The key factor expected to drive growth in the coronary stent market is the increasing prevalence of coronary artery diseases (CADs) caused by an accumulation of plaque in the artery. This prompted a demand for percutaneous coronary intervention therapies employing stents.
• For instance, in December 2023, according to an article published by the Australian Institute of Health and Welfare, based on self-reported data from the Australian Bureau of Statistics 2020–21 National Health Survey, an estimated 571,000 Australians aged 18 and older (2.9% of the adult population) had CHD in 2020–21 (ABS 2022). As people age, the prevalence of CHD rises quickly, impacting around 1 in 9 (11%) adults over the age of 75. A projected 56,700 adults over the age of 25 experienced an acute coronary event in 2020, which is equivalent to 155 heart attacks or unstable angina episodes every day. 12,900 (or 6%) of these were fatal.

An increase in geriatric population worldwide

• An aging population is increasingly driving the epidemic of cardiovascular disease (CVD). A key risk factor for CAD is aging, and the incidence of CAD tends to increase with population aging. With coronary artery disease (CAD), the blood supply to the heart muscle is decreased due to narrowing or blockage of the coronary arteries. Coronary stents are often required for this illness to relieve symptoms and restore blood flow. Due to the cumulative consequences of aging, such as atherosclerosis and other comorbidities, older people may have more complex instances of CAD. These complicated instances frequently call for more involved procedures, such as using many stents or specialist methods.

Coronary Stent Market Restrains:

Expensive procedures combined with extensive regulatory measures

• The major restraining factors for the target market are the high cost of such procedures and the tight regulatory measures that must be followed. Particularly in areas with little funding, the expense of PCI operations and stents can be quite taxing on patients and healthcare systems. The stringent regulatory procedures for new stent devices further impede innovation and delay market introduction.

Coronary Stent Market is segmented based on product type, material type, end-user, and region.

Product Type Insights

• Drug-Eluting Stent: Drug-eluting stent is a dominating segment of this sector for the target market. A drug-eluting stent is covered in a controlled-release drug to prevent blood clot formation in stents. A stent blood clot may result in a heart attack and subsequent obstruction (restenosis). Nowadays, when combined with prescription anticoagulant medicine, upgraded drug-eluting stents are considered safe and successful for most patients. Compared to bare-metal stents, drug-eluting stents generally have a lower risk of restenosis. The most popular kind of stent used to treat a heart artery blockage is a drug-eluting stent. Drug-eluting stents have proven to be an effective treatment for many heart patients, averting the need for more invasive operations like coronary artery bypass surgery.
• Bare-Metal Stent: Bare metal stents are thin wire tubes resembling mesh that isn't coated or covered. After a few weeks of implantation, bare metal stents should ideally be sealed into the vessel wall by a fresh layer of endothelial cells. In percutaneous coronary intervention (PCI), bare-metal coronary artery stents are utilized for several indications, such as multiple-vessel disease, acute myocardial infarction (MI), and stable and unstable angina. The materials used to make current bare metal stents (BMSs) are platinum chromium, cobalt chromium, or stainless steel.
• Bioresorbable Vascular Stent: A bioabsorbable vascular stent (BVS) is a recently developed stent that may offer several advantages in concept. Bioresorbable stents are one new method for treating coronary artery disease in interventional cardiology. Bioresorbable technology was developed to address issues with late in-stent restenosis and vascular caging that plague existing metallic drug-eluting stents. A bioresorbable stent is designed to maintain a vessel temporarily until it is broken down and reabsorbed by the body. This process aids in vascular repair and vasomotion restoration.

Material Type Insights

• Metallic: Metallic stents dominate this sector's segment for the target market. Stents used in coronary arteries are constructed from metal mesh. It includes various materials like cobalt-chromium (CoCr), platinum chromium (Pt-Cr), stainless steel, nickel-titanium, and others.
• Cobalt-Chromium (CoCr): Cobalt-chromium (CoCr) stents emerged primarily due to the requirement for a new generation of coronary stents that maintained or enhanced previous versions' deliverability, safety, and effectiveness. These stents are more radiopaciously conductive and more resilient than steel stents. As a result, the chance of thrombosis can be decreased by using a smaller mesh size. They are also very biocompatible; nonetheless, there is still a risk of restenosis with this kind of stent. Therefore, it must be watched out for.
• Platinum Chromium (Pt-Cr): Platinum chromium (Pt-Cr) possesses potential advantages, including thinner struts and increased flexibility, making it a relatively recent alternative. Because it offers more flexibility, it might better adapt to complex anatomy.
• Stainless Steel: Stainless steel is among stents' most often utilized substances. Some features are X-ray visibility, high biocompatibility, and fairly elastic and robust consistency. These characteristics make this kind of stent ideal for balloon implantation and averting abrupt vascular closure.
• Nickel Titanium: Nickel-titanium alloy is more regularly utilized for self-expanding stents and is more popularly known as nitinol. It is frequently employed in carotid stents. Because these stents often have a diameter greater than the vessel in which they are placed, the vascular walls can withstand steady pressure. Since nitinol is a form memory alloy, its primary benefit is its high flexibility.
• Others: This category may include novel metallic alloys and some biocompatible polymers still under vigorous research and development procedures to be proven safe and effective in individuals.

End-User Insights

• Hospitals: Hospitals, as an end-user type, are a dominating segment of this sector for the target market. The main factor behind this is the rise in important surgeries—such as angioplasty—that are done mostly in hospital settings. A hospital is the best option because it has sophisticated facilities for intricate operational operations.
• Cardiac Center: These specialty clinics frequently have the newest equipment and highly skilled personnel for stent insertion.
• Others: This category includes ambulatory surgical centers, which may provide stent procedures for a limited number of patients, usually those deemed to be at reduced risk.

Regional Insights:

Coronary Stent Market Regional Insights

• North American market is estimated to witness a significantly high revenue share over the forecast period, owing to a rise in sedentary lifestyles that leads to obesity and other cardiovascular disorders, including heart attack, stroke, ischemic heart disease (IHD), etc.
• The Asia Pacific market is estimated to witness the fastest revenue share due to the increase in the aging population, which is driving an increase in cardiovascular treatments, including stenting. This is also driven by the availability of stents at cheaper rates and government rules that cap the cost of coronary stents in nations like India.
• European market is expanding steadily due to various factors like the emergence of unhealthy eating patterns, a rise in smoking rates, and an increasingly inactive lifestyle, all of which lead to compromised immune systems and elevated stress levels, which in turn raise the risk of heart disease. In addition to driving market expansion, these variables fiercely support heart disease's slow, natural progression over time.
• The Latin American market is an emerging region and is observing an increasing frequency of cardiovascular disease as a result of things like poor lifestyle choices and restricted access to healthcare services that prevent disease. Also, stents are now more affordable owing to expanding economies, which also means higher healthcare spending and discretionary money.
• The Middle East and Africa market is in its developmental stages. Several nations' economies are expanding quickly, which could result in higher healthcare costs and market expansion opportunities. Increased rates of cardiovascular illnesses in the area are another factor driving it.

Report Scope:

Segments Covered in the Report:

This report forecasts revenue growth at global, regional, and country levels and provides an analysis of the latest industry trends and opportunities in each of the sub-segments from 2024 to 2034. For the purpose of this study, has segmented the Coronary Stent Market report based on product type, material type, end-user, and region:

Coronary Stent Market, By Product Type:

• Drug-Eluting Stent
• Bare-Metal Stent
• Bioresorbable Vascular Stent

Coronary Stent Market, By Material Type:

• Metallic
• Cobalt Chromium (CoCr)
• Platinum Chromium (Pt-Cr)
• Stainless Steel
• Nickel Titanium
• Others

Coronary Stent Market, By End-User:

• Hospitals
• Cardiac Center
• Others

Coronary Stent Market, By Region:

• North America
  • U.S.
  • Canada
• Europe
  • Germany
  • UK
  • France
  • Russia
  • Italy
  • Rest of Europe
• Asia Pacific
  • China
  • India
  • Japan
  • South Korea
  • Rest of Asia Pacific
• Latin America
  • Brazil
  • Mexico
  • Rest of Latin America
• Middle East & Africa
  • GCC
  • Israel
  • South Africa
  • Rest of Middle East & Africa

The key players operating the Coronary Stent Market include STENTYS SA, Biotronik SE & Co. KG, Braun Melsungen AG, Terumo Corporation, Medtronic plc, MicroPort Scientific Corporation, Meril Life Sciences Pvt. Ltd., Abbott Laboratories, Boston Scientific Corporation, and Biosensors International Group, Ltd.

• STENTYS SA*
• Biotronik SE & Co. KG
• Braun Melsungen AG
• Terumo Corporation
• Medtronic plc
• MicroPort Scientific Corporation
• Meril Life Sciences Pvt. Ltd.
• Abbott Laboratories
• Boston Scientific Corporation
• Biosensors International Group, Ltd.